Oncology | Pfizer China

Worldwide, breast cancer is the most common invasive cancer, with more than 2.2 million impacted annually. Metastatic breast cancer (mBC), the most advanced stage of breast cancer in which the cancer has spread beyond the breast to other parts of the body (i.e., organs, bones), remains an incurable disease. As a result of earlier screening, increased awareness, and better treatments, breast cancer deaths have continued to decrease in older women. From 2013 to 2018, the death rate went down by 1% per year.

Lung cancer remains the leading cause of cancer-related death among men and women globally, and the global five-year survival rate at 17.8 percent is much lower than leading cancers. Lung cancer is notoriously difficult to treat due to the heterogeneous nature of the disease, variability in testing rates and the onset of drug resistance. These challenges necessitate an individualized approach to treatment, ensuring people with lung cancer receive the right drug at the right time.

The genitourinary (GU) tract is comprised of urinary, reproductive and adrenal system organs. Organs of the genitourinary tract include the prostate (males only), kidneys and bladder. GU cancers are pervasive and notoriously hard to treat, despite available therapies. Each person’s cancer behaves differently, requiring a tailored, individualized approach for each individual.

Blood cancers strike ruthlessly at any age. Some come fast and take lives within weeks or months. Others develop in the bones and blood over time, requiring intense and aggressive treatment interventions that are traumatic, emotionally overwhelming, and expensive. More than 1 million people worldwide were diagnosed with a blood cancer in 2020, representing almost 6% of all cancer diagnoses globally. In 2020, more than 700,000 people worldwide died from a form of blood cancer.